7月16日，科伦博泰生物盘中下跌3.45%，报515.5港元，成交额1.22亿港元。公司前一交易日公布核心产品TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阴性NSCLC的III期研究达到主要终点，当日股价大涨逾11%。今日早盘开涨4.19%后迅速回落，呈现典型的利好兑现冲高回调走势。
此外，生物科技板块整体承压，信达生物跌2.52%、康方生物跌1.26%、三生制药跌1.16%，板块情绪偏弱加剧回调。公司7月10日完成的27.23亿港元配售（折价约8.52%）亦对短期股价形成压力。高盛今日维持公司"买入"评级。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.